254 results about "Pox virus" patented technology

The invention discloses a primer combination for detecting monkey pox viruses and identifying monkey pox viruses Ia, Ib and II, and belongs to the technical field of molecular biology, the nucleotide sequences of specific primers and probes are shown as SEQ ID NO.1-SEQ ID NO.12, and the primer combination aims at solving the problem that in the prior art, new evolutionary branch Ib types of monkey pox viruses cannot be accurately typed, and the detection sensitivity is high. According to the present invention, the defects that the monkey pox virus and the orthopox virus have the cross reaction are overcome, the genome difference of different evolutionary branches is analyzed through the bioinformatics system, the primer probe composition capable of simultaneously detecting the monkey pox virus and carrying out accurate typing is analyzed and screened, and the primer combination can detect 200 copies / mL of the monkey pox virus with high specificity and high sensitivity. Meanwhile, detection of the monkey pox virus and identification of the types Ia, Ib and II of the monkey pox virus are realized in a reaction system, so that different monkey pox branches can be distinguished, and treatment and prevention can be performed in a more targeted manner.

The invention discloses an anti-monkey pox virus antibody as well as a preparation method and application thereof. The invention specifically discloses eight kinds of antibodies (A35R-9E4, A35R-9F8, A35R-10C4, A35R-10D5, A35R-10E7, A35R-10H6, A35R-18E2 and A35R-18H2) which have very good affinity to monkey pox virus A35R protein, and the eight kinds of antibodies have very good neutralizing activity and a certain in-vivo protection effect.

The invention relates to the fields of biology, medicine and clinic. In particular to application of PAICS as a target spot in developing or screening reagents for preventing and / or treating orthopoxvirus infection, and application of inhibiting a synthetic pathway of purine nucleotide and / or inhibiting a metabolic pathway of folic acid in preparing reagents for treating and / or preventing orthopoxvirus infection diseases. In order to restrain the infection of orthopoxvirus, the inventor team uses a CRISPR / Cas9 technology to carry out generic genome screening on host cells infected by orthopoxvirus, determines a host-dependent gene PAICS gene in the orthopoxvirus infection process, and verifies and clarifies the virus-dependent mechanism of the gene; in order to deal with the global continuous orthopoxvirus infection problem, the invention plays an important role in the development and screening of future related prevention or treatment drugs, and also expands the new clinical application of existing drugs including methotrexate, mercaptopurine, mizoribine and the like.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof in the central nervous system or ex vivo. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a disease (e.g., a neurological disease), preventing a disease (e.g., neurological disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof.

The invention discloses a monoclonal antibody for resisting monkey pox virus M1R protein and application of the monoclonal antibody. The invention specifically discloses a plurality of antibodies (M1R-12E10, M1R-12H5, M1R-12H6, M1R-24A7 and M1R-24H1) which have very good specificity and affinity to an M1R protein, and the antibodies have very good neutralizing activity and a certain in-vivo protection effect.

The invention provides an ultra-sensitive and high-specificity primer pair and crRNA for instantly detecting monkey pox virus, a kit and application thereof, and belongs to the technical field of molecular biological detection. The primer pair and the crRNA disclosed by the invention comprise a front primer, a rear primer and the crRNA. According to the primer pair and the crRNA disclosed by the invention, immediate detection of the MIRRA-CRISPR-Cas13a mediated monkey pox virus can be realized, the detection sensitivity is high, the specificity is strong, and rapid, accurate and sensitive identification of the monkey pox virus can be realized. Through implementation, experiments show that the detection limit of the primer pair and the crRNA for detecting the monkey pox virus can reach 14.4 copies / mL, and the primer pair and the crRNA have important significance on accurate clinical diagnosis of the monkey pox virus and epidemiological investigation.

The invention discloses a monkey pox virus epitope mRNA composition and application thereof, and relates to the technical field of biological medicines. The monkey pox virus epitope mRNA composition comprises mRNA encoding an epitope or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with the epitope and having the same immunogenicity. The vaccine can generate a high-level immune protection effect aiming at the monkey pox virus, can be used for preparing a medicine for preventing and treating the monkey pox virus, and has a wide application prospect clinically.

The invention provides an immunochromatographic test strip for quantitatively detecting monkey pox virus based on fluorescent latex microspheres, which takes europium chelate Eu (DBM) 3Phen-loaded monodisperse carboxylated polystyrene copolymer microspheres as a signal substance, and the microspheres are subjected to acid-base treatment before loading to loosen the surface structure of the microspheres so as to improve the loading capacity; the surface compound of the test strip is prepared by coupling carboxyl on the surface of the microsphere with an antibody. The invention also discloses a preparation method of the test strip. The kit is convenient for rapidly and accurately detecting the monkey pox virus, and has the characteristics of simplicity, rapidness, no toxicity and low cost.

Provided herein are antibodies and functional fragments thereof for the treatment or prophylaxis of viral diseases, such as poxvirus diseases, such as Chenpox and monkey pox. Any antibody or functional fragment thereof described herein may be an engineered antibody or an engineered antibody fragment. In addition, provided herein are compositions and pharmaceutical compositions containing one or more antibodies or functional fragments thereof. Also provided herein are kits containing one or more antibodies or functional fragments thereof, as well as methods, dosing regimens, dosage amounts, and pathways for administering one or more antibodies and one or more functional fragments thereof. Finally, methods of making the antibodies and functional fragments thereof are provided.

The application relates to an antibody against monkeypox virus and a preparation method thereof, and the humanized monkeypox virus antibody H3-14A7 is obtained by screening memory B cells of a human antibody against H3 specific binding mouse. The H3-14A7 has the characteristics of strong monkeypox virus binding capacity, good in-vitro neutralization, large affinity and in-vivo protection.

The invention discloses a kit for simultaneously detecting bluetongue virus, foot and mouth disease virus, schmallenberg virus, peste des petits ruminants virus and sheep pox virus, and belongs to the technical field of virus detection. The kit comprises primers as shown in SEQ ID NO. 1 to SEQ ID NO. 18 and a probe as shown in SEQ ID NO. 18. After a single system of bluetongue virus, foot-and-mouth disease virus, schmallenberg virus, peste des petits ruminants virus and capripox virus is tested, a sextuple system containing an interior label is established, and through testing of indexes such as linearity, minimum detection limit, specificity, precision and repeatability, NTC repetition, comparison of multiple fluorescent RT-PCR and single fluorescent RT-PCR, the kit can be used for detecting the virus resistance of the peste des petits ruminants virus and the capripox virus. The currently developed fluorescent RT-PCR multiple detection kit for the sheep respiratory tract syndromes completely meets the development requirement, the specificity is high, the sensitivity is high, and the lowest detection limit can reach 10 Copi / mu L or below.

The invention relates to the technical field of medicines, in particular to application of salinomycin in preparation of oral medicines for preventing or treating monkey pox virus (MPXV) infection. Salinomycin is a polyether antibiotic produced by actinomycetes. It is found for the first time that salinomycin can efficiently inhibit monkey pox virus infection on the cell culture level, and can significantly improve the survival rate of mice infected with monkey pox virus in small animal living bodies. More importantly, salinomycin can be administered by oral administration, has good bioavailability and safety, and provides a brand new treatment means for monkey pox virus infection. The medicinal value of salinomycin in resistance to monkey pox virus infection is reported for the first time at home and abroad, and the application prospect of salinomycin in the field of viral disease treatment is expanded.

The invention relates to a monkey pox virus nano vaccine based on an STING agonist and silicon nanoparticles as well as a preparation method and application of the monkey pox virus nano vaccine. The nano vaccine comprises a monkey pox virus antigen, the silicon nanoparticles and the STING agonist, the monkey pox virus antigen is combined to the surface of the silicon nanoparticle through a DogTag-DogCatcher system; the STING agonist is connected to the surface of the monkey pox virus antigen. The monkey pox virus antigen is covalently coupled with the silicon nanoparticles, and the antigen is displayed on the surfaces of the particles in a specific spatial orientation manner, so that the multivalence and accessibility of the antigen are enhanced, the shielding effect of the silicon nanoparticles on epitopes of the antigen is reduced, and the immune response induced by the vaccine is higher than that of a monomer immunogen protein.

The invention provides a novel vaccine based on an adenovirus vector and application thereof. According to the present invention, the suitable monkey pox virus gene is selected for the first time, and is efficiently integrated with the chimpanzee virus vector (AdC68) to prepare the ideal virus vaccine, and the ideal virus vaccine is suitable for nasal cavity immunization and muscle immunization, and has good nasal cavity immunization effect. The novel monkey pox vaccine can be effectively used for prevention and control of monkey pox virus and vaccinia virus infection, and the two types of viruses are considered.

The invention discloses an application of Arcyriaflavin A or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating monkey pox virus infection. The invention finds that the Arcyriaflavin A can obviously inhibit the replication of the monkey pox virus in a Vero cell, and the IC50 of the Arcyriaflavin A for inhibiting the Ib branch monkey pox virus and the IC50 of the Arcyriaflavin A for inhibiting the IIb branch monkey pox virus are 0.66 mu M and 0.96 mu M respectively. The invention also verifies that the Arcyriaflavin A has extremely low toxicity to Vero cells, and the toxicity CC50 of the Arcyriaflavin A to the cells is 41.51 mu M when the Arcyriaflavin A is used for inhibiting the proliferation of the monkey pox virus, so that the Arcyriaflavin A can be used for effectively inhibiting the replication of the monkey pox virus within the safe use range of the Arcyriaflavin A. The invention provides a new choice for the prevention and treatment of monkey pox, and has important significance for the prevention and treatment of monkey pox.

The present invention relates to a recombinant chimeric antigen targeting poxvirus (particularly monkeypox virus), a subunit vaccine thereof, and its application. The recombinant chimeric antigen of the present invention comprises two immunogens arranged in a specific manner: monkeypox virus A35 protein or its antigenic fragment (or its derivative peptide segment) and monkeypox virus M1 protein or its antigenic fragment (or its derivative peptide segment), which can stimulate immune responses against two infectious virus particles: intracellular mature virus particles (IMV) and extracellular enveloped virus particles (EEV), thereby efficiently stimulating specific immune protection against monkeypox virus. In addition, the poxvirus vaccine of the present invention also has good safety, rapid responsiveness and production capacity support, and has excellent clinical application prospects.

The invention relates, in general, to synthetic chimeric poxviruses, compositions comprising such viruses, and the development and use of systems and methods for producing such synthetic chimeric poxviruses. The synthetic chimeric poxviruses are well suited for live virus vaccines and pharmaceutical formulations.

The invention provides a novel bovine nodular skin disease virus LSDV-125 strain and application thereof in vaccine preparation, and belongs to the technical field of virology. The problem that a novel vaccine strain which is clear in genetic background, stably weakened in virulence and capable of inducing broad-spectrum immune response is urgently needed is solved. The invention relates to a sheep pox virus strain, in particular to a sheep pox virus LSDV-125 which is named sheep pox virus LSDV-HLJ-2023, has the preservation number of CCTCC (China Center for Type Culture Collection) NO: V202537, and is preserved in China Center for Type Culture Collection on May 13, 2025. The method is mainly used for developing efficient and safe attenuated live vaccines.

The invention discloses a method for detecting high sensitivity of monkey pox virus by a one-pot method RPA-CRISPR based on temperature control, and the method comprises the following steps: establishing a temperature-controlled RPA and CRISPR-Cas12b combined detection method, which is called as CRATS for short, by utilizing the reaction temperature difference between RPA amplification and CRISPR-Cas12b cutting; the reaction process in a tube system is regulated and controlled by stages through a temperature switching strategy: target amplification is completed at 37 DEG C firstly, then the temperature is raised to 60 DEG C, Cas12b cutting is started, so that sequential separation of amplification and cutting reactions is realized, and finally detection is realized through a fluorescence signal released by molecular beacon breakage. The problem that Cas enzyme cutting activity interferes with the amplification process in a traditional one-pot method reaction is solved, the detection sensitivity and specificity are improved, and a new technical means is provided for on-site rapid detection of the monkey pox virus.

An oncolytic poxvirus encoding a truncated human CD19 is used in conjunction with a chimeric antigen receptor to treat solid tumors.

An mRNA molecule is disclosed. The mRNA molecule contains a polynucleotide encoding an M1R antigen of Mpox and a polynucleotide encoding an RBD antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and further contains a polynucleotide encoding an A35R antigen of Mpox. An application of the mRNA molecule in the preparation of an mRNA vaccine against Mpox or SARS-CoV-2 is further disclosed. Compared to an mRNA vaccine encoding separately corresponding antigens, the provided mRNA vaccine encoding a fusion antigen can induce considerable or even higher-level neutralizing antibody responses against Mpox and SARS-CoV-2, and provides 100% immune protection against the lethal challenge of ectromelia virus. The vaccine is obtained by synthesizing a single mRNA molecule and encapsulating the single mRNA within lipid nanoparticles. Therefore, the single-component fusion mRNA vaccine has a wider application prospect than multivalent mRNA vaccine compositions.

The present invention relates to specific monoclonal antibodies and their applications. The amino acid sequence of the light chain CDR1 of the monoclonal antibody is shown in SEQ ID No. 1, the amino acid sequence of CDR2 is shown in SEQ ID No. 2, and the amino acid sequence of CDR3 is shown in SEQ ID No. 3; the amino acid sequence of the heavy chain CDR1 of the monoclonal antibody is shown in SEQ ID No. 4, the amino acid sequence of CDR2 is shown in SEQ ID No. 5, and the amino acid sequence of CDR3 is shown in SEQ ID No. 6. The present invention uses recombinant monkeypox virus surface protein E8L as an antigen. The screened monoclonal antibodies have good affinity for the recombinant monkeypox virus surface protein E8L at the molecular and cellular levels, can significantly inhibit the infection efficiency of VACV replication-deficient strains in VERO cells, and have good in vitro neutralization effect against monkeypox virus.

The invention relates to the field of biological medicine, in particular to application of disulram in preparation of an orthopoxvirus inhibitor, the disulram is specifically combined with palmitic acid on MPXV gp045 membrane protein to show a remarkable inhibition effect on orthopoxviruses, and when IC50 of the disulram is 825nM, diffusion of the orthopoxviruses can be remarkably inhibited; in HeLa and Huh7.5. 1 cells, when IC50 is 3022nM and 7125nM respectively, formation of EEV can be remarkably inhibited, so that further transmission of orthopoxvirus is prevented, and a more comprehensive intervention means is provided for treatment of orthopoxvirus resistance.

The invention provides a monkey pox virus nucleic acid detection kit and a preparation method thereof. The kit is used for qualitatively detecting monkey pox virus nucleic acid in vitro. Specific primers and probes are designed for the target F3L gene and the internal standard RNase P gene respectively, and the primer and probe combination is excellent in specificity, stability, compatibility, anti-interference performance and instrument adaptability, high in accuracy and sensitivity, easy to operate and high in detection speed. According to the kit disclosed by the invention, a freeze-drying reagent is prepared by utilizing the primer probe, so that the kit can completely get rid of the limitation of a cold chain, convenience is provided for remote areas lacking cold chain transportation and long-distance transportation, and the transportation and storage cost is greatly reduced. The monkey pox virus nucleic acid detection kit is simple in preparation method, good in reproducibility and easy to realize large-scale production and clinical application.

This invention relates to monoclonal antibodies for detecting A35R protein and their applications. This invention screened six antibodies, including antibody 4E7, antibody 11G12, antibody 6F10, antibody 6C11, antibody 18C3, and antibody 23A7. Specifically, this invention discloses the amino acid sequences of the heavy chain variable region and the light chain variable region of the above antibodies, as well as the amino acid sequences of their complementarity-determining regions and framework regions. Antibodies 4E7 and 11G12 can bind not only to the A35R-MPXV protein but also to its homologs A35R-CPXV, A35R-VTT8, and A35R-Variola. Antibodies 6F10, 6C11, 23A7, and 18C3 can specifically recognize the A35R-MPXV protein. The monoclonal antibodies described above all exhibit high binding capacity to the A35R protein, making them suitable for the sensitive and specific detection and prevention of monkeypox virus A35R protein. They can also be used clinically for the diagnosis and treatment of monkeypox virus infection-related diseases.

The present invention relates to 2'-fluoro-6'-methylene carbocyclic nucleosides and nucleotides, pharmaceutical compositions containing these nucleosides and nucleotides, and their use in the treatment or prophylaxis of poxvirus infections and secondary disease states and conditions thereof.

Provided herein are methods of producing immunoglobulin Y (IgY) antibodies against monkeypox virus. The method includes immunizing hens with a peptide encoding at least one immunogenic domain of A29 fusion protein from the monkeypox virus and isolating the IgY antibodies against the A29 fusion protein from yolks of eggs laid by the immunized hens. Pharmaceutical compositions containing the IgY antibodies and methods of inhibiting or treating monkeypox virus infection are also provided.

This application discloses antibodies against monkeypox virus, their preparation methods, and applications. Specifically, this application discloses eight antibodies (A35R-9E4, A35R-9F8, A35R-10C4, A35R-10D5, A35R-10E7, A35R-10H6, A35R-18E2, and A35R-18H2) that have excellent affinity for the monkeypox virus A35R protein, and that they exhibit good neutralizing activity and certain in vivo protective effects.

The invention relates to the field of biotechnology and targeted therapy, in particular to a recombinant construct, a recombinant oncolytic virus and construction and application of the recombinant oncolytic virus. The virus takes a wild poxvirus genome as a skeleton, thymokinase TK genes are deleted through homologous recombination, and a poxvirus P-se / l promoter is used for promoting expression of a CD19 membrane localization antibody. The constructed recombinant oncopoxvirus aCD19-TM-OVV can improve the infection efficiency and gene delivery efficiency on B lymphoma in a CD19 antigen target-dependent manner, promote virus replication of the oncopoxvirus in CD19 positive B lymphoma cells, and significantly enhance the tumor growth inhibition effect on the CD19 positive B lymphoma cells in vitro and in mouse B lymphoma models.

The invention discloses a primer probe composition for detecting measles, parotitis, rubella and varicella virus nucleic acid and application, and belongs to the technical field of virus nucleic acid detection. The invention protects the real-time fluorescent PCR detection primer and probe composition for simultaneously or respectively detecting measles, parotitis, rubella and varicella viruses and different subtype strains, and plays a positive role in respectively or simultaneously performing clinical detection and prevention and diagnosis on different strains of several viruses. The detection method disclosed by the invention is simple, time-saving and labor-saving, wide in application range and convenient to use, and measles, rubella, parotitis and varicella viruses and different strains can be rapidly detected at the same time by amplifying a PCR reaction once. The primer probe composition provided by the invention is high in detection sensitivity, strong in specificity and good in repeatability, can realize rapid differential diagnosis on clinical samples, enables different patients to obtain timely targeted prevention and treatment, and has important significance for development of quadruple vaccines.